Fierce Pharma

As BridgeBio's Attruby launch accelerates, CEO shrugs off recent EU pricing pressure fears

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 | When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing pressure on Attruby and provided more evidence of the drug's strong launch,

BridgeBio outlines transition to cash generation by 2028 with $600M profit target, driven by pipeline advances and Attruby growth

Management expects cash burn to hold steady through 2026 and start declining by the end of next year, driven by increasing Attruby revenues and improved operating leverage. Kumar said, "Our current pipeline will begin to generate cash in late '27 and will be a cash generation engine by 2028."
InvestorsHub on MSN

BridgeBio rallies on strong phase 3 data for achondroplasia pill

BridgeBio Pharma (NASDAQ:BBIO) shares climbed about 9% on Thursday after the biotech group unveiled positive Phase 3 topline results for its oral drug infigratinib in achondroplasia, marking what it said were the first statistically significant gains in body proportionality seen in the condition.
Nasdaq

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on November 17, 2025, the ...

BridgeBio Pharma, Inc.: BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

BridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscript Attruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the greatest TTR stabilization on the market (=90%) and the most rapid benefit on clinical outcomes observed within 1 month,
BioPharma Dive

BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis

The latest in a string of clinical wins, the late-stage data gives the company strong footing to compete with BioMarin's top seller.

BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial

Feb 12 (Reuters) - BridgeBio Pharma said its experimental therapy boosted growth rates in children with a rare genetic disorder that causes dwarfism, sending the company's shares 7% higher on Thursday.

BridgeBio to Participate in March Investor Conferences

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences: TD Cowen 46th Annual Healthcare Conference,